This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carcelain, G.
Right arrow Articles by Autran, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carcelain, G.
Right arrow Articles by Autran, B.

 Previous Article  |  Next Article 

Journal of Virology, January 2001, p. 234-241, Vol. 75, No. 1
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.1.234-241.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Transient Mobilization of Human Immunodeficiency Virus (HIV)-Specific CD4 T-Helper Cells Fails To Control Virus Rebounds during Intermittent Antiretroviral Therapy in Chronic HIV Type 1 Infection

Guislaine Carcelain,1 Roland Tubiana,2 Assia Samri,1 Vincent Calvez,3 Constance Delaugerre,3 Henri Agut,3 Christine Katlama,2 and Brigitte Autran1,*

Laboratoire d'Immunologie Cellulaire, CNRS-UMR 7527,1 Service des Maladies Infectieuses,2 and Laboratoire de Virologie,3 Hôpital Pitié-Salpétriêre, Paris, France

Received 7 July 2000/Accepted 29 September 2000

Immune control of human immunodeficiency virus (HIV) is not restored by highly active antiretroviral therapies (HAART) during chronic infection. We examined the capacity of repeated structured therapeutic interruptions (STI) to restore HIV-specific CD4 and CD8 T-cell responses that controlled virus production. Eleven STI (median duration, 7 days; ranges, 4 to 24 days) were performed in three chronically HIV-infected patients with CD4 counts above 400/mm3 and less than 200 HIV RNA copies/ml after 18 to 21 months of HAART; treatment resumed after 1 week or when virus became detectable. HIV-specific T-cell responses were analyzed by proliferation, gamma interferon (IFN-gamma ) production, and enzyme-linked immunospot assays. Seven virus rebounds were observed (median, 4,712 HIV-1 RNA copies/ml) with a median of 7 days during which CD4 and CD8 counts did not significantly change. After treatment resumed, the viral load returned below 200 copies/ml within 3 weeks. Significant CD4 T-cell proliferation and IFN-gamma production against HIV p24 appeared simultaneously with or even before the virus rebounds in all patients. These CD4 responses lasted for less than 3 weeks and disappeared before therapeutic control of the virus had occurred. Increases in the numbers of HIV-specific CD8 T cells were delayed compared to changes in HIV-specific CD4 T-cell responses. No delay or increase in virus doubling time was observed after repeated STI. Iterative reexposure to HIV during short STI in chronically infected patients only transiently mobilized HIV-specific CD4 T1-helper cells, which might be rapidly altered by virus replication. Such kinetics might explain the failure at delaying subsequent virus rebounds and raises concerns about strategies based on STI to restore durable HIV-specific T-cell responses in chronic HIV infection.

* Corresponding author. Mailing address: Laboratoire d'Immunologie Cellulaire, CNRS-UMR 7527, Hôpital Pitié-Salpétriêre, Paris, France. Phone: 33 (1) 42.17.74.81. Fax: 33 (1) 42.17.74.90. E-mail: brigitte.autran{at}psl.ap-hop-paris.fr.

Journal of Virology, January 2001, p. 234-241, Vol. 75, No. 1
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.1.234-241.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Pialoux, G., Quercia, R. P., Gahery, H., Daniel, N., Slama, L., Girard, P.-M., Bonnard, P., Rozenbaum, W., Schneider, V., Salmon, D., Guillet, J.-G. (2008). Immunological Responses and Long-Term Treatment Interruption after Human Immunodeficiency Virus Type 1 (HIV-1) Lipopeptide Immunization of HIV-1-Infected Patients: the LIPTHERA Study. CVI 15: 562-568 [Abstract] [Full Text]  
  • Younes, S.-A., Trautmann, L., Yassine-Diab, B., Kalfayan, L. H., Kernaleguen, A.-E., Cameron, T. O., Boulassel, R., Stern, L. J., Routy, J.-P., Grossman, Z., Dumont, A. R., Sekaly, R.-P. (2007). The Duration of Exposure to HIV Modulates the Breadth and the Magnitude of HIV-Specific Memory CD4+ T Cells. J. Immunol. 178: 788-797 [Abstract] [Full Text]  
  • Samri, A., Durier, C., Urrutia, A., Sanchez, I., Gahery-Segard, H., Imbart, S., Sinet, M., Tartour, E., Aboulker, J.-P., Autran, B., Venet, A., the ANRS ELISpot Standardization Group, (2006). Evaluation of the Interlaboratory Concordance in Quantification of Human Immunodeficiency Virus-Specific T Cells with a Gamma Interferon Enzyme-Linked Immunospot Assay. CVI 13: 684-697 [Abstract] [Full Text]  
  • Bower, M., Nelson, M., Young, A.M., Thirlwell, C., Newsom-Davis, T., Mandalia, S., Dhillon, T., Holmes, P., Gazzard, B.G., Stebbing, J. (2005). Immune Reconstitution Inflammatory Syndrome Associated With Kaposi's Sarcoma. JCO 23: 5224-5228 [Abstract] [Full Text]  
  • Soldan, S. S., Plassmeyer, M. L., Matukonis, M. K., Gonzalez-Scarano, F. (2005). La Crosse Virus Nonstructural Protein NSs Counteracts the Effects of Short Interfering RNA. J. Virol. 79: 234-244 [Abstract] [Full Text]  
  • Kaufmann, D. E., Bailey, P. M., Sidney, J., Wagner, B., Norris, P. J., Johnston, M. N., Cosimi, L. A., Addo, M. M., Lichterfeld, M., Altfeld, M., Frahm, N., Brander, C., Sette, A., Walker, B. D., Rosenberg, E. S. (2004). Comprehensive Analysis of Human Immunodeficiency Virus Type 1-Specific CD4 Responses Reveals Marked Immunodominance of gag and nef and the Presence of Broadly Recognized Peptides. J. Virol. 78: 4463-4477 [Abstract] [Full Text]  
  • Weintrob, A. C., Giner, J., Menezes, P., Patrick, E., Benjamin, D. K. Jr, Lennox, J., Pilcher, C. D., Eron, J. J., Hicks, C. B. (2003). Infrequent Diagnosis of Primary Human Immunodeficiency Virus Infection: Missed Opportunities in Acute Care Settings. Arch Intern Med 163: 2097-2100 [Abstract] [Full Text]  
  • Fagard, C., Oxenius, A., Gunthard, H., Garcia, F., Le Braz, M., Mestre, G., Battegay, M., Furrer, H., Vernazza, P., Bernasconi, E., Telenti, A., Weber, R., Leduc, D., Yerly, S., Price, D., Dawson, S. J., Klimkait, T., Perneger, T. V., McLean, A., Clotet, B., Gatell, J. M., Perrin, L., Plana, M., Phillips, R., Hirschel, B. (2003). A Prospective Trial of Structured Treatment Interruptions in Human Immunodeficiency Virus Infection. Arch Intern Med 163: 1220-1226 [Abstract] [Full Text]  
  • Abbas, U. L., Mellors, J. W. (2002). Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: Risk without reward. Proc. Natl. Acad. Sci. USA 99: 13377-13378 [Full Text]  
  • Oxenius, A., Price, D. A., Gunthard, H. F., Dawson, S. J., Fagard, C., Perrin, L., Fischer, M., Weber, R., Plana, M., Garcia, F., Hirschel, B., McLean, A., Phillips, R. E. (2002). Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc. Natl. Acad. Sci. USA 99: 13747-13752 [Abstract] [Full Text]  
  • Lori, F., Foli, A., Lisziewicz, J. (2002). Structured treatment interruptions as a potential alternative therapeutic regimen for HIV-infected patients: a review of recent clinical data and future prospects. J Antimicrob Chemother 50: 155-160 [Abstract] [Full Text]  
  • Walmsley, S., Loutfy, M. (2002). Can Structured Treatment Interruptions (STIs) Be Used as a Strategy to Decrease Total Drug Requirements and Toxicity in HIV Infection?. J Int Assoc Physicians AIDS Care (Chic Ill) 1: 95-103 [Abstract]  
  • Cainelli, F., Vento, S., Nieuwkerk, P. T., Lange, J. M. A. (2002). Full Adherence to HAART: Is It Really Necessary?. Arch Intern Med 162: 944-945 [Full Text]  
  • Lori, F., Lisziewicz, J. (2001). Structured Treatment Interruptions for the Management of HIV Infection. JAMA 286: 2981-2987 [Abstract] [Full Text]  
  • Pacanowski, J., Kahi, S., Baillet, M., Lebon, P., Deveau, C., Goujard, C., Meyer, L., Oksenhendler, E., Sinet, M., Hosmalin, A. (2001). Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 98: 3016-3021 [Abstract] [Full Text]  
  • Ortiz, G. M., Wellons, M., Brancato, J., Vo, H. T. T., Zinn, R. L., Clarkson, D. E., Van Loon, K., Bonhoeffer, S., Miralles, G. D., Montefiori, D., Bartlett, J. A., Nixon, D. F. (2001). Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc. Natl. Acad. Sci. USA 10.1073/pnas.221452198v1 [Abstract] [Full Text]  
  • Bahr, G. M., Darcissac, E. C. A., Casteran, N., Amiel, C., Cocude, C., Truong, M.-J., Dewulf, J., Capron, A., Mouton, Y. (2001). Selective Regulation of Human Immunodeficiency Virus-Infected CD4+ Lymphocytes by a Synthetic Immunomodulator Leads to Potent Virus Suppression In Vitro and in hu-PBL-SCID Mice. J. Virol. 75: 6941-6952 [Abstract] [Full Text]  
  • Ortiz, G. M., Wellons, M., Brancato, J., Vo, H. T. T., Zinn, R. L., Clarkson, D. E., Van Loon, K., Bonhoeffer, S., Miralles, G. D., Montefiori, D., Bartlett, J. A., Nixon, D. F. (2001). Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc. Natl. Acad. Sci. USA 98: 13288-13293 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»